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Abstract
Background Pancreatic cancer (PC) patients have multiple risk factors for sarcopenia and loss of skeletal muscle mass
(LSMM), which may cause greater treatment toxicities, reduced response to cancer therapy, prolonged hospitalization,
impaired quality of life, and worse prognosis.
Methods This is a retrospective study on advanced PC patients treated at the Department of Oncology of Udine, Italy, from
January 2012 to November 2017. Among 162 patients who received chemotherapy, 94 consecutive patients with an available
computed tomography (CT) scan were retrospectively analyzed. The primary objective of our study was to explore if an early
LSMM ≥ 10% (measured at first radiological evaluation and compared with baseline) and/or baseline sarcopenia may impact
prognosis. Baseline sarcopenia was defined according to Prado’s criteria. Skeletal muscle area was measured as cross-sectional
areas (cm2) using CT scan data through the Picture archiving and communication system (PACS) image system.
Results In the whole cohort, 48% of patients were ≤70 years old, and 50% had metastatic disease.
At baseline, 73% of patients had sarcopenia, and 16% presented a visceral fat area ≥ 44 cm2/m2. Overall, 21% experienced an
early LSMM ≥ 10%. Approximately 33% of sarcopenic patients at baseline and ~35% of patients with early LSMM ≥ 10% had a
body mass index > 25 kg/m2. Of note, 71% of patients were evaluated by a nutritionist, and 56% received a dietary supple-
mentation (oral and/or parenteral). After a median follow-up of 30.44months, median overall survival (OS) was 11.28months,
whereas median progression-free survival (PFS) was 5.72months. By multivariate analysis, early LSMM ≥ 10% was significantly
associated with worse OS [hazard ratio (HR): 2.16; 95% confidence interval (CI) 1.23–3.78; P = 0.007] and PFS (HR: 2.31; 95% CI
1.30–4.09; P = 0.004). Moreover, an exploratory analysis showed that inflammatory indexes, such as neutrophil–lymphocyte
ratio variation, impact early LSMM ≥ 10% (odds ratio 1.31, 95% CI 1.06–1.61, P = 0.010).
Conclusions Early LSMM ≥ 10% has a negative prognostic role in advanced PC patients. Further prospective investigations
are needed to confirm these preliminary data.
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Introduction
Pancreatic cancer (PC) is a very rapidly progressive disease
characterized by several genetic and molecular alterations,
as well as poor prognosis. Despite being a relatively rare
type of cancer, recent estimates predict an increase in its
incidence over the next years.1 Unfortunately, effective
therapies capable of changing the disease’s natural history
are still lacking. PC patients have shorter survival and an
increased risk of distant metastases.2,3 Furthermore, the
prognosis of these patients is conditioned by a higher inci-
dence of malnutrition or cachexia, present in 70–80% of
PC patients, responsible for at least 20% of all deaths.4–7
In fact, multiple risk factors for loss of skeletal muscle mass
(LSMM) due to cancer-related factors and medical treat-
ment concur to cause more treatment toxicities, asthenia,
fatigue, reduced response to cancer therapy, prolonged
hospitalization, impaired quality of life, and, therefore, a
worse prognosis.2,6,8,9 However, the identification of
patients with muscle loss has become increasingly difficult,
because ~40–60% of cancer patients are overweight or
obese, even in the metastatic setting.3 Sarcopenia was
defined by Evans as LSMM, which results in decreased
strength and aerobic capacity and, thus, functional capacity.
The pathogenesis of sarcopenia includes a systemic inflam-
matory reaction, involving anabolic and catabolic pathways
responsible for skeletal muscle physiology.10 Firstly, inflam-
matory mediators such as cytokines [tumour necrosis factor
(TNF-α), interleukins (ILs)] and C-reactive protein are
released from the liver into the bloodstream, increasing
the lipid and protein catabolism and, therefore, inhibiting
the anabolic pathways. Moreover, they act on the central
nervous system and visceral fat [visceral adipose tissue
(VAT)], causing anorexia and fatigue.11
The best way to diagnose sarcopenia is by measuring
the lean mass by either dual-energy x-ray absorptiome-
try (DXA) or computed tomography (CT) scan. Although
DXA scans produce highly accurate results, they lack
the ability to discriminate among lean and adipose
tissue sub-compartments. Conversely, CT image analysis
at the third lumbar vertebra allows to distinguish
adipose tissue (including visceral, subcutaneous, and
intramuscular) from muscle tissue,6–8 and it has been
validated as a reliable method for whole-body composi-
tion assessment.
Recently, the use of gold standard methods for body
composition assessment, including CT, has simplified the
diagnosis of cancer-related sarcopenia, thus better defining
its prevalence. However, the impact survival of cachexia,
including weight loss and/or sarcopenia, in PC patients has
still been poorly studied.
Based on these premises, the aim of this study was to
evaluate the prognostic impact of body composition among
PC patients.
Material and methods
Study design
This is an observational, retrospective study that examined
data of 165 advanced PC patients treated at the Oncology
Department of Udine, Italy, from January 2012 to November
2017. A cohort of 94 consecutive patients with the availability
of CT scan has been analysed. All patients had confirmed PC
and the consent to the use of clinical data, rendered anony-
mous, for purposes of clinical research, epidemiology, training,
and study of diseases for patients who have died and informed
consent of the study for patients who are alive. The study was
approved by the Departmental Review Board and by the Ethics
Committee (approved in May 2018, Protocol Number 16662).
Data have been obtained from electronic medical records ac-
cording to strict privacy standards. The study aimed to charac-
terize the prognostic impact of LSMM in advanced PC patients
during first-line treatment (i.e. baseline and after 12 weeks)
analysing clinical outcome. Moreover, we evaluated the asso-
ciation among LSMM and inflammation index [neutrophil–
lymphocyte ratio (NLR), lactate dehydrogenase (LDH), albu-
min] and with early dietary supplementation (defined as die-
tary implementation in the first 3 months of first-line
chemotherapy). Progression-free survival (PFS) was defined
as time from first-line chemotherapy until progression of dis-
ease or death from any cause. Overall survival (OS) was de-
fined as the time between treatment start and death from
any cause.
Skeletal muscle mass assessment
Computed tomography scans, performed within 30 days since
first-line treatment start, were retrospectively evaluated. Skel-
etal muscle area wasmeasured as a cross-sectional area in cm2
using routine CT scan data through the PACS image system.
Skeletal muscle index (SMI) was calculated as a cross-sectional
area of muscle (cm2) at the L3 level divided by the square of
the height (m2). In particular, psoas, erector spinae, quadratus
lumborum, transversus abdominis, external and internal
oblique muscles of the abdomen, and rectus abdominis mus-
cle were evaluated. Sarcopenia has been defined according
to Prado’s criteria [SMI < 53 cm2/m2 for men with body mass
index (BMI) > 25, SMI < 43 cm2/m2 for men with BMI < 25,
SMI < 41 cm2/m2 for women],2,12–14 and early LSMM during
chemotherapy has been defined as a decrease of SMI > 10%
at first CT evaluation (approximately after 3 months).15
Blood sample analysis
Lactate dehydrogenase, albumin and C-reactive protein levels
were classified according to a cut-off of 480 U/L, 35 g/L, and
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5mg/L, respectively. NLR was defined as the absolute neutro-
phil count divided by the absolute lymphocyte count. Full
blood count data were eligible for analysis if performed
within 1 month before the start of first-line chemotherapy.
Statistical analysis
Patients’ clinico-pathological characteristics were summarized
through descriptive analysis. Categorical variables were
described through frequency distribution, whereas continu-
ous variables will be reported through median range. Clinico-
pathological variables were compared between sarcopenic
and non-sarcopenic patients, and between patients who had
an LSMM ≥ 10% and <10%.
The association of early LSMM with inflammation index
was explored by Wilcoxon rank-sum test or Kruskal–Wallis
test, as statistically appropriate. The impact of clinico-
pathological features determining early LSMM and early
nutritional intervention was analysed with logistic regression.
Prognostic factors in terms of OS were tested in both univar-
iate and multivariate models by Cox regression with 95% CI.
Differences in survival were tested by log-rank test and
represented by Kaplan–Meier survival curves.
A two-sided P < 0.05 was considered statistically signifi-
cant. Statistical analysis was performed using STATA
[StataCorp (2015) Stata Statistical Software: Release 14.2,
College Station, TX, USA: StataCorp LP].
Results
This study included 94 patients with a diagnosis of advanced
PC (patients’ characteristics are shown in Table 1). In the
whole cohort, 48% of patients were younger than 70 years,
and 32% of patients had an Eastern Cooperative Oncology
Group performance status (PS) of 0, and 50% had metastatic
disease. Approximately 88% of patients had tumour histology
or tumour cytology available showing a diagnosis of adeno-
carcinoma. The remaining 12% presented with clinical, radio-
logical, and/or bio-humoral features suggestive of pancreatic
adenocarcinoma. Only 2% of patients received radiotherapy
in multiple fractions. In addition, most of the patients (70%)
did not receive surgery.
Overall, after a median follow-up of 30.44 months, median
OS was 11.28 months (25th–75th percentiles: 4.90–
22.06 months), whereas median PFS was 5.72 months
(25th–75th percentiles: 2.79–9.6 months).
As for anthropometric characteristics, median body
weight of the whole cohort was 68.5 kg and median BMI
was 24.1 kg/m2. Overall, 16% of patients presented a
VAT ≥ 44 cm2/m2 (defined as visceral area divided by the
square of the height), and 73% were sarcopenic at baseline
(characteristics of sarcopenic patients were displayed in
Table 1 Patients’ characteristics
Variable No. (n = 94) %
Age
<70 years 45 48
≥70 years 49 52
Gender
Male 52 55
Female 42 45
Site of primary tumour
Head 51 54
Body–tail 43 46
ECOG PS at first-line chemotherapy start
0 30 32
≥1 64 68
Stage at first-line chemotherapy start
Locally advanced 47 50
Metastatic disease 47 50
Metastatic site at first-line chemotherapy start
Bone 2 2
Liver 43 46
Lymph nodes 21 22
Lung 12 13
Peritoneum 7 8
BMI (kg/m2)
18.5–25 60 64
>25 34 36
Visceral fat (cm3/h2)
<44 79 84
≥44 15 16
Sarcopenia at first-line chemotherapy start
Yes 69 73
No 25 27
Nutritional assessment (since diagnosis)
Yes 67 71
No 27 29
Nutritional supplementation (since diagnosis)
Yes 53 56
No 41 44
Type of first-line chemotherapy
Single agent 25 27
Gemcitabine
Capecitabine
Combination regimen 53 56
Gemcitabine plus nab-paclitaxel
Gemcitabine plus cisplatin
Fluorouracil, irinotecan, and oxaliplatin
Other 16 17
Lines of therapy for metastatic disease
1 51 54
2 27 29
3 16 17
Laboratory parameter at first-line
chemotherapy start
LDH (UI/L)
≤480 60 64
>480 14 15
Missing 20 21
Albumin (g/L)
≤35 20 21
>35 63 67
Missing 11 12
C-reactive protein (mg/L)
≤5 18 19
>5 40 43
Missing 36 38
CA 19-9 (UI/L)
≤60 18 19
>60 74 79
Missing 2 2
ECOG, Eastern Cooperative Oncology Group.
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Table 2). Overall, 21% of population experienced an early
LSMM ≥ 10% at first radiological assessment. On the other
hand, 5%of population experienced aweight loss ≥ 10%. Char-
acteristics of patients experiencing an early LSMM ≥ 10% are
shown in Table 2. Among sarcopenic individuals, 12 patients
experienced an early LSMM ≥ 10%. Approximately 33% of
sarcopenic individuals at baseline and ~35% of patients with
early LSMM had a BMI > 25 kg/m2.
Through univariate and multivariate analyses, we found
that metastatic disease at diagnosis, VAT ≥ 44 cm2/m2, and
an early LSMM ≥ 10% were negative prognostic factors in
terms of both OS and PFS (Tables 3 and 4). More specifically,
the median OS was 8.78 months for patients with an early
LSMM ≥ 10% vs. 12.85 months for patients with an early
LSMM < 10% [hazard ratio (HR): 2.16; 95% CI 1.23–3.78;
P = 0.007, Figure 1]. Furthermore, median PFS was
4.14 months for the first group vs. 7.27 months for the sec-
ond group (HR: 2.31; 95% CI 1.30–4.09; P = 0.004; Figure 2).
To explore possible parameters that could predict an
early LSMM superior or inferior to 10%, we performed a lo-
gistic regression revealing an association with NLR variation
[odds ratio (OR) 1.31, 95% CI 1.06–1.61, P = 0.010] and LDH
variation (OR 1.01, 95% CI 1.00–1.01, P = 0.020) (Figure 3).
No association was observed with C-reactive protein levels,
Lymphocyte-to-monocytes ratio (LMR) variation, CA 19-9
variation, albumin variation, BMI variation, or a body
weight change after 3 months since diagnosis.
Overall, 71% of patients were evaluated by a nutritionist,
and 56% of patients received a dietary supplementation (oral
and/or parenteral). To explore possible factors associated
with an earlier supplementation, we found an association
only with body weight variation (OR 1.11, 95% CI 1.01–1.22,
P = 0.024). No association was observed with a BMI variation,
PS Karnofsky variation, baseline BMI, SMI variation, site of
primary tumour, or age (Table 5, Figure 4). Only body weight
variation at first radiological assessment during chemother-
apy showed an association with the decision to prescribe an
early supplementation.
Discussion
Recent literature has focused on the prognostic impact of
sarcopenia and its post-operative role in respect of complica-
tion.1 However, most of these studies included patients who
received surgery, and, unfortunately,7,16,17 few data are avail-
able for advanced PC patients.
In the present study, we examined a cohort of 94
advanced PC patients, exploring in a real-world scenario the
prognostic impact of baseline sarcopenia (at the diagnosis
of advanced PC), and of an early LSMM ≥ 10% (after
3 months). Additional anthropometric measures were
evaluated (BMI, weight loss, and baseline VAT).
Approximately 73% of patients were sarcopenic at baseline
according to previous data,2,6,7 and most of them had normal
BMI (median BMI: 24.1 kg/m2). Furthermore, 33% of
sarcopenic patients and 35% of patients with early LSMM
had a BMI > 25 kg/m2. Of note, sarcopenic obesity may be
potentially misleading because sarcopenia is also present
among normal and obese patients.2,18,19 Therefore, in these
cases, a skeletal muscle wasting may be masked, leading to
greater toxicity and potentially serious adverse events to an-
ticancer treatment.5,20
Therefore, the use of BMI only is not reliable for nutritional
assessment, because LSMM could be independent from
weight loss and patients with similar weight or BMI may have
a significant difference in body composition.21–24 In our
cohort, 21% of PC patients experienced an early LSMM ≥ 10%.
Among sarcopenic patients, ~21% were subject to further loss
of muscle mass ≥ 10%.
By univariate analysis, metastases at diagnosis, early PS
loss according Karnofsky ≥ 20%, VAT ≥ 44 cm2/m2, and early
LSMM ≥ 10% had a prognostic role. In multivariate analysis,
in addition to the stage of diagnosis, only early LSMM ≥ 10%
and VAT ≥ 44 cm2/m2 was statistically relevant and associ-
ated with worse prognosis in term of OS and PFS.
More recently, a retrospective analysis conducted on 782
PC patients found no significant prognostic association with
survival outcomes for muscle attenuation.25 The considerable
number of patients with early-stage disease included in the
study, ~35% of the whole cohort, may explain the discrep-
ancy with our results, considering the possible differences in
prognosis, the potential metabolic differences between
advanced and early muscle wasting, and the recovering from
muscle wasting after curative surgery.
Moreover, in contrast to Danai and colleagues who defined
muscle attenuation as the average Hounsfield attenuation of
all pixels in the muscle area, we evaluated the early LSMM as
a decrease of SMI > 10% at first CT evaluation analysed in
advanced PC.25
Cachexia in cancer patients is a well-established negative
prognostic factor,2 and sarcopenia may be one of its compo-
nents, despite that the two conditions are very different.
Cachexia is defined as a body weight loss over 12 months of
5% or more26; conversely, sarcopenia defines metabolic
disorders that include LSMM, atrophy, fatigue, and reduction
of muscular strength. During this process, muscle fibres are
replaced by fibrotic tissue, resulting in neuromuscular junc-
tion degeneration, increased levels of reactive oxygen species
alterations, and altered muscle metabolism.27,28 Nowadays,
the best index to identify sarcopenic patients is still under
debate, as well as the nutritional follow-up.4
Many studies are trying to clarify the molecular pathways
underlying muscle wasting. The effect of systemic inflamma-
tion on muscle wasting could play a crucial role, because
pro-inflammatory factors such as cytokines (TNF-α, IL-1, IL-
6, and interferon γ), acute phase protein (C-reactive protein),
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Table 2 Characteristic of sarcopenic patients and patients with Δ SMI ≥ 10%
Variable
Sarcopenic patients
n = 69
Patients with Δ SMI ≥ 10%
n = 20
No. % No. %
Age
<70 years 30 43 10 50
≥70 years 39 57 10 50
Gender
Male 39 57 11 55
Female 30 43 9 45
Site of primary tumour
Head 38 55 8 40
Body–tail 31 45 12 60
Previous surgery
No 50 72 — —
Yes 19 28
Diabetes
No 51 74 — —
Yes 18 26
ECOG PS at first-line chemotherapy start
0 20 29 6 30
≥1 49 71 14 70
Stage at first-line chemotherapy start
Locally advanced 32 46 11 55
Metastatic disease 37 54 9 45
Metastatic site at first-line chemotherapy start
Bone 2 3 1 5
Liver 34 49 9 45
Lymph nodes 15 21 6 25
Lung 10 14 3 15
Peritoneum 5 7 1 5
BMI (kg/m2)
18.5–25 46 67 13 65
>25 23 33 7 35
Visceral fat (cm3/h2)
<44 59 86 17 85
≥44 10 14 3 15
Nutritional assessment (since diagnosis)
Yes 50 72 17 85
No 19 28 3 15
Nutritional supplementation (since diagnosis)
Yes 40 58 13 65
No 29 42 7 35
Type of first-line chemotherapy
Single agent 20 29 5 25
Combination regimen 38 55 9 45
Other 11 16 6 30
Lines of therapy for metastatic disease
1 37 53 13 65
2 21 30 4 20
3 11 17 3 15
Laboratory parameter at first-line chemotherapy start
LDH (UI/L)
≤480 41 59 17 85
>480 11 16 1 5
Missing 17 25 2 10
Albumin (g/L)
≤35 14 20 6 30
>35 48 70 14 70
Missing 7 10 — —
C-reactive protein (mg/L)
≤5 13 19 6 30
>5 32 46 6 30
Missing 24 35 8 40
CA 19-9 (UI/L)
≤60 12 17 4 20
>60 55 80 14 70
Missing 2 3 2 10
Δ, from baseline to first radiological assessment; ECOG, Eastern Cooperative Oncology Group.
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Table 3 Univariate and multivariate analyses for overall survival
Variable
Univariate analysis Multivariate analysis
HR 95% CI P HR 95% CI P
Age
≥70 vs. <70 years 1.40 0.89–2.20 0.141
Stage at diagnosis
Metastatic disease vs. locally advanced 2.11 1.36–3.28 0.001 2.25 1.35–3.76 0.002
Diabetes
Yes vs. no 1.05 0.65–1.69 0.838
ECOG PS
≥1 vs. 0 1.44 0.88–2.34 0.141
BMI
>25 vs. 18.5–25 kg/m2 1.00 0.97–1.57 0.973
Visceral fat
≥44 vs. <44 cm3/h2 2.19 1.23–3.91 0.008 2.77 1.31–5.87 0.008
Site of primary tumour
Body–tail vs. head 1.36 0.88–2.12 0.160
Δ SMI
≥10% vs. <10% 1.92 1.12–3.31 0.018 2.16 1.23–3.78 0.007
Δ Karnofsky PS
≥20% vs. <20% 1.87 1.02–3.44 0.042 1.18 0.52–2.69 0.686
Nutritional assessment
Yes vs. no 1.03 0.63–1.68 0.905
Nutritional supplementation
Yes vs. no 1.43 0.91–2.23 0.112
Δ Body weight
≥10% vs. <10% 2.46 0.97–6.25 0.057
Sarcopenia
Yes vs. no 1.16 0.69–1.94 0.565
Early nutritional assessment
Yes vs. no 1.23 0.79–1.92 0.342
Early nutritional
supplementation
Yes vs. no 1.49 0.95–2.33 0.077
The bold values are variables statistically significant in univariate and multivariate analysis.
Δ, from baseline to first radiological assessment; ECOG, Eastern Cooperative Oncology Group.
Table 4 Univariate and multivariate analyses for progression-free survival
Variable
Univariate analysis Multivariate analysis
HR 95% CI P HR 95% CI P
Age
≥70 vs. <70 years 1.19 0.77–1.84 0.420
Stage at diagnosis
Metastatic disease vs. locally advanced 1.88 1.22–2.90 0.004 1.84 1.11–3.04 0.017
Diabetes
Yes vs. no 0.98 0.62–1.56 0.961
ECOG PS
≥1 vs. 0 1.40 0.89–2.22 0.143
BMI
>25 vs. 18.5–25 kg/m2 0.84 0.53–1.32 0.460
Site of primary tumour
Body–tail vs. head 1.06 0.69–1.63 0.762
Δ SMI
≥10% vs. <10% 1.82 1.06–3.13 0.029 2.31 1.30–4.09 0.004
Visceral fat
≥44 vs. <44 cm3/h2 2.45 1.34–4.49 0.003 2.98 1.41–6.28 0.004
Δ Karnofsky PS
≥20% vs. <20% 1.97 1.08–3.60 0.027 1.43 0.63–3.23 0.383
Nutritional assessment
Yes vs. no 0.77 0.48–1.24 0.294
Nutritional supplementation
Yes vs. no 1.06 0.68–1.63 0.791
Δ Body weight
≥10% vs. <10% 2.60 1.03–6.59 0.043
The bold values are variables statistically significant in univariate and multivariate analysis.
Δ, from baseline to first radiological assessment; ECOG, Eastern Cooperative Oncology Group.
6 D. Basile et al.
Journal of Cachexia, Sarcopenia and Muscle 2019
DOI: 10.1002/jcsm.12368
and metabolic factors impact metabolism, contributing to
LSMM.29
In our study, we exploratorily evaluated the association be-
tween the early LSMMand systemic inflammation indexes and
their impact on early LSMM considering NLR, LDH, C-reactive
protein, and albumin variation at 3 months after first-line
treatment. We found a significant association with NLR
variations and LDH variations, although the LDH variation
was not clinically relevant. No association was observed with
other inflammatory indexes or with body weight loss. Notably,
markers of systemic inflammation, such as NLR, are correlated
with high levels of cytokines resulting in modulation of several
factors (IGF-1/Akt/mTOR axis, FoxOs, NF-κB, and MAPK)
favouring a catabolic state.27 More specially, IGF-1 stimulates
protein synthesis and promotes muscle hypertrophy;
Akt/protein kinase B and FoxO are responsible for muscle ho-
meostasis by regulating cell metabolism, growth, and survival.
However, the main inhibitor of muscle growth is myostatin. It
is produced by skeletal myocytes and negatively impact
muscle growth through the interaction with IGF-1–Akt signal-
ling, mediated by the transcription factors small mothers
against decapentaplegic 2 and 3.10,30 Moreover, TNF-α and
IL-6 inhibit myocyte differentiation promoting muscle atrophy
and insulin resistance, leading to muscle wasting and increas-
ing lipid deposition in skeletal muscle tissue.11,28 LSMM could
contribute to local inflammation, leading to further break-
down and enhancing systemic inflammation.11,29,31 Previous
studies have confirmed the association of many of these
inflammatory biomarkers with sarcopenia.27,32,33 In our study,
we exploratorily evaluate the variation of these inflammatory
indexes, but some of them were not associated with early
LSMM, probably owing to the small sample size of the study
and its retrospective nature.
In our cohort, 71% of patients received a nutritional assess-
ment during any anticancer treatment line, and ~56% were
evaluated in the first 3 months of first-line chemotherapy.
Moreover, 56% received a nutritional supplementation (oral
and/or parenteral), and only 37% received an early nutritional
intervention, although many of them were already
sarcopenic. Overall, 85% of patients with early LSMM
received a nutritional assessment, and only 55% received an
early nutritional assessment. However, 30% received a
dietary supplementation, and 25% received an early
nutritional intervention (Table 2).
Surprisingly, early nutritional assessment and early dietary
intervention did not impact prognosis in term of OS. Appar-
ently, this finding was discordant with previous data.34–36
Therefore, we evaluated which factors were associated with
early dietary supplementation, and only body weight loss
was associated with an early dietary supplementation. How-
ever, as weight loss and BMI do not impact patient survival,
nor does LSMM, it is useless to consider only these factors
to perform a nutritional evaluation and implementation.
Figure 1 Overall survival. CI, confidence interval; HR, hazard ratio;
LSMM, loss of skeletal muscle mass.
LSMM <10% 12.85 months
LSMM>=10% 8.78 months
HR: 2.16; 95%; p=.007
CI 1.23-3.78
Figure 2 Progression-free survival. CI, confidence interval; HR, hazard ratio; LSMM, loss of skeletal muscle mass.
LSMM <10% 7.27 mo
LSMM>=10% 4.14 mo
HR: 2.31; p=.004
95% CI 1.30-4.09; 
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Figure 3 Association of inflammatory indexes with early nutritional intervention. LSMM, loss of skeletal muscle mass.
Table 5 Logistic regression—univariate for early dietary supplementation
Variable
Univariate analysis
HR 95% CI P
Δ: Body weight 1.10 1.01–1.18 0.035
≤10% vs. >10%
BMI at first-line chemotherapy
start (kg/m2)
0.74 0.53–1.04 0.091
>25 vs. ≤25
Δ SMI 0.53 0.16–1.66 0.277
≤10% vs. >10%
Site of primary tumour 0.99 0.43–2.31 0.996
Body–tail vs. head
Age 0.79 0.34–1.84 0.595
≥70 vs. <70 years
Δ Karnofsky PS 1.00 0.97–1.03 0.796
≤20% vs. >20%
The bold values are variables statistically significant in univariate
and multivariate analysis.
Δ, from baseline to first radiological assessment.
Figure 4 Association of body weight variation with early nutritional
intervention.
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Therefore, only a radiologic evaluation of LSMM provides an
objective parameter that every clinician can use to monitor
the nutritional status of PC patients.
Conclusions
Pancreatic cancer is a very rapidly progressive disease charac-
terized by metabolic disorders that can easily lead to muscle
mass depletion. The present study showed that an early
LSMM ≥ 10% has a negative prognostic impact on advanced
PC patients. On the other hand, baseline sarcopenia, weight
loss, and BMI did not impact prognosis. Moreover, some
inflammatory biomarkers, such as NLR variation, have an
impact on an early LSMM ≥ 10%. Contrarily, early nutritional
assessment and intervention were not associated with prog-
nosis, and we showed that only body weight loss was associ-
ated with early nutritional implementation. Considering that
weight loss and BMI did not impact patient survival, nor does
LSMM, it is useless to consider only weight loss to perform a
nutritional evaluation. In conclusion, to our knowledge, this is
the first work to demonstrate the prognostic value of SMI
loss during anticancer therapy independent from weight loss
or gain. Therefore, to further evaluate the prognostic impact
of an early nutritional treatment, we will provide a prospec-
tive Phase II study.
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